Literature DB >> 20512435

Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations.

Vimon Tantishaiyakul1, Krit Suknuntha, Visit Vao-Soongnern.   

Abstract

The crystalline states of cimetidine and piroxicam, when coprecipitated from solvents containing 1:1 mole ratio, were transformed to amorphous states as observed using powder X-ray diffraction (PXRD). Amorphous forms of drugs generally exhibit higher water solubility than crystalline forms. It is therefore interesting to investigate the interactions that cause the transformation of both the crystalline drugs. Intermolecular interactions between the drugs were determined using Fourier-transform infrared spectroscopy (FTIR) and solid-state (13)C CP/MAS NMR. Molecular dynamic (MD) simulation was performed for the first time for this type of study to indicate the specific groups involved in the interactions based on radial distribution function (RDF) analyses. RDF is a useful tool to describe the average density of atoms at a distance from a specified atom. FTIR spectra revealed a shift of the C identical withN stretching band of cimetidine. The (13)C CP/MAS NMR spectra indicated downfield shifts of C(11), C(15) and C(7) of piroxicam. RDF analyses indicated that intermolecular interactions occurred between the amide oxygen atom as well as the pyridyl nitrogen of piroxicam and H-N(3) of cimetidine. The hydrogen atom (O-H) at C(7) interacts with the N(1) of cimetidine. Since the MD simulation results are consistent with, and complementary to the experimental analyses, such simulations could provide a novel strategy for investigating specific interacting groups of drugs in coprecipitates, or in amorphous mixtures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512435      PMCID: PMC2902308          DOI: 10.1208/s12249-010-9461-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  27 in total

1.  What is the true solubility advantage for amorphous pharmaceuticals?

Authors:  B C Hancock; M Parks
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  The polymorphism of cimetidine.

Authors:  B Hegedüs; S Görög
Journal:  J Pharm Biomed Anal       Date:  1985       Impact factor: 3.935

3.  The in vitro effects of piroxicam and meloxicam on canine cell lines.

Authors:  C Knottenbelt; G Chambers; E Gault; D J Argyle
Journal:  J Small Anim Pract       Date:  2006-01       Impact factor: 1.522

4.  Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: a technical note.

Authors:  Vimon Tantishaiyakul; Pattakarn Permkam; Krit Suknuntha
Journal:  AAPS PharmSciTech       Date:  2008-01-15       Impact factor: 3.246

5.  Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.

Authors:  S A Said; A M Foda
Journal:  Arzneimittelforschung       Date:  1989-07

Review 6.  Antiinflammatory drugs and gastric mucosal damage.

Authors:  E L Semble; W C Wu
Journal:  Semin Arthritis Rheum       Date:  1987-05       Impact factor: 5.532

Review 7.  Drug therapy: Cimetidine.

Authors:  W Finkelstein; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

8.  Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin.

Authors:  Jun Liu; Liyan Qiu; Jianqing Gao; Yi Jin
Journal:  Int J Pharm       Date:  2006-02-03       Impact factor: 5.875

Review 9.  Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review).

Authors:  Florence Lefranc; Paul Yeaton; Jacques Brotchi; Robert Kiss
Journal:  Int J Oncol       Date:  2006-05       Impact factor: 5.650

10.  Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.

Authors:  V Tantishaiyakul; N Kaewnopparat; S Ingkatawornwong
Journal:  Int J Pharm       Date:  1999-04-30       Impact factor: 5.875

View more
  1 in total

1.  Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.

Authors:  Ji-Hun An; Changjin Lim; Alice Nguvoko Kiyonga; In Hwa Chung; In Kyu Lee; Kilwoong Mo; Minho Park; Wonno Youn; Won Rak Choi; Young-Ger Suh; Kiwon Jung
Journal:  Pharmaceutics       Date:  2018-09-05       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.